FDA approves GE’s SenoClaire

The FDA has approved SenoClaire, GE’s breast tomosynthesis device that was developed in collaboration with Massachusetts General Hospital.

SenoClaire uses a short sweep of low-dose x-ray around the breast, taking nine exposures in a “step-and-shoot” method, according to GE.

There are currently 180 units installed across Europe, Australia, Latin America, Southeast Asia and the Middle East.

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Trimed Popup
Trimed Popup